With the newly created AbbVie (NYSE:ABBV) drawing so much of its revenue from a single source, many investors are worried about what the company will look like after January 2017, when Humira goes over its patent cliff. In this video, Motley Fool health-care bureau chief Brenton Flynn discusses AbbVie's dividend and whether it can really continue to grow. In particular, he explains why strong cash flow for the company over the next few years could very likely mean dividend growth.
Brenton Flynn and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.